WallStreetZenWallStreetZen

NASDAQ: RZLT
Rezolute Inc Stock

$2.55+0.31 (+13.84%)
Updated Mar 28, 2024
RZLT Price
$2.55
Fair Value Price
$0.26
Market Cap
$101.04M
52 Week Low
$0.72
52 Week High
$2.69
P/E
-2.32x
P/B
1.1x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$56.83M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$53M
Beta
0.59
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RZLT Overview

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RZLT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RZLT ($2.55) is overvalued by 862.73% relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RZLT ($2.55) is not significantly undervalued (862.73%) relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RZLT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RZLT due diligence checks available for Premium users.

Be the first to know about important RZLT news, forecast changes, insider trades & much more!

RZLT News

Valuation

RZLT fair value

Fair Value of RZLT stock based on Discounted Cash Flow (DCF)
Price
$2.55
Fair Value
$0.26
Overvalued by
862.73%
RZLT ($2.55) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RZLT ($2.55) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RZLT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RZLT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.32x
Industry
14.26x
Market
44.51x

RZLT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.1x
Industry
6.21x
RZLT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RZLT's financial health

Profit margin

Revenue
$0.0
Net Income
-$13.9M
Profit Margin
0%
RZLT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$102.2M
Liabilities
$10.4M
Debt to equity
0.11
RZLT's short-term assets ($96.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RZLT's short-term assets ($96.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RZLT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RZLT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$13.0M
Investing
$17.8M
Financing
-$293.0k
RZLT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RZLT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
RZLT$101.04M+13.84%-2.32x1.10x
CELU$101.35M+5.87%-0.52x3.35x
VANI$101.71M0.00%-3.70x4.90x
ANIX$99.53M-3.41%-9.18x4.05x
ATHA$105.02M+7.03%-0.89x0.81x

Rezolute Stock FAQ

What is Rezolute's quote symbol?

(NASDAQ: RZLT) Rezolute trades on the NASDAQ under the ticker symbol RZLT. Rezolute stock quotes can also be displayed as NASDAQ: RZLT.

If you're new to stock investing, here's how to buy Rezolute stock.

What is the 52 week high and low for Rezolute (NASDAQ: RZLT)?

(NASDAQ: RZLT) Rezolute's 52-week high was $2.69, and its 52-week low was $0.72. It is currently -5.2% from its 52-week high and 254.17% from its 52-week low.

How much is Rezolute stock worth today?

(NASDAQ: RZLT) Rezolute currently has 39,625,271 outstanding shares. With Rezolute stock trading at $2.55 per share, the total value of Rezolute stock (market capitalization) is $101.04M.

Rezolute stock was originally listed at a price of $20.00 in Nov 10, 2020. If you had invested in Rezolute stock at $20.00, your return over the last 3 years would have been -87.25%, for an annualized return of -49.67% (not including any dividends or dividend reinvestments).

How much is Rezolute's stock price per share?

(NASDAQ: RZLT) Rezolute stock price per share is $2.55 today (as of Mar 28, 2024).

What is Rezolute's Market Cap?

(NASDAQ: RZLT) Rezolute's market cap is $101.04M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Rezolute's market cap is calculated by multiplying RZLT's current stock price of $2.55 by RZLT's total outstanding shares of 39,625,271.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.